Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.5.4 (
SOR
)
720
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A combination of two enzymes,
phospholipase D
(PL D) and C (PL C), was investigated for the production of two lysophospholipids, 1-lauroyl-rac-glycerophosphate (1-LGP) and 1-lauroyl-dihydroxyacetonephosphate (1-LDHAP). The high transphosphatidylation ability of
phospholipase D
from Streptomyces sp. allowed the formation of 1-lauroyl-phosphatidylglycerol (1-LPG) and 1-lauroyl-phosphatidyldihydroxyacetone (1-LPDHA) from phosphatidylcholine (PC) and 1-monolauroyl-rac-glycerol (1-MLG) and 1-lauroyl-dihydroxyacetone (1-
MDHA
), respectively. A two-phase system, diethyl ether/water, was chosen for the convenience of the recovery of the water insoluble products. A similar two-phase system was used for hydrolysis of the complex phospholipids by phospholipase C form Bacillus cereus, which released both lysophospholipids. Only trace amounts of phosphatidic acid (PA) were detected showing that the enzyme is highly selective for the release of the diacylglycerol and 1-lauroyl-rac-glycerophosphate and 1-lauroyl-dihydroxyacetonephosphate.
...
PMID:Two-enzyme system for the synthesis for 1-lauroyl-rac-glycerophosphate (lysophosphatidic acid) and 1-lauroyl-dihydroxyacetonephosphate. 1066 9
